Patrick Caubel

Pfizer (United States)

Papers

1

Total Citations

86

H-Index

1

About

Dr. Patrick Caubel is a leading voice in pharmacovigilance, where his work focuses on harnessing artificial intelligence and automation to revolutionize drug safety monitoring. His most cited contribution, "Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing" (2018, 86 citations), demonstrates a pivotal shift in the field. In this landmark study, Dr. Caubel piloted the use of AI and robotic process automation to automate adverse event case processing—historically the largest cost driver for pharmaceutical safety budgets. By proving the feasibility of this approach, he laid the groundwork for a new era of efficiency and accuracy in pharmacovigilance, reducing human error while accelerating the detection of safety signals. His work not only offers a compelling solution to an industry-wide challenge but also inspires a generation of researchers to explore how emerging technologies can transform public health protection. Dr. Caubel’s research remains essential reading for anyone interested in the intersection of machine learning, regulatory science, and patient safety.

Research Focus

Key Achievements

1
H-Index
1
Papers
86
Total Citations
86
Avg Citations/Paper
🏆 Most Cited Paper
Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
86 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago